Elon Musk and his Neuralink company's attempt to begin testing brain chips in humans has been rejected by the FDA, according to a report by Reuters.
The request was submitted to the agency last year but according to Reuters, the FDA identified several problematic factors with the technology, including the chip's lithium battery and the potential for small wires to move to other areas of the brain.
"Neuralink doesn't appear to have the mindset and experience that's needed to get this to market anytime soon," Kip Ludwig, former program director for neural engineering at the U.S. National Institute of Health.
There was also a concern of whether or not the chip could be removed without inflicting damage to brain tissue.
What Exactly Is Neuralink?
Musk has claimed the technology could be life-changing for people suffering from paralysis, enabling them to communicate and walk, or it could help repair visual impairment in people.
The chip is supposed to process brain signals that are then transmitted to a device. While human trials for Neuralink have not commenced, there have been versions of the tech that reportedly had some success in animals. However, the company faced pushback and a probe from the U.S. Department of Agriculture after animal cruelty concerns were raised.
Last month Neuralink admitted that at least one monkey was euthanized because of a surgical complication.
Alexander Reed, CFA and CIO for Envisage Wealth, breaks down why he thinks rates could stay higher for longer and why real estate, utilities, and regional banks are sectors to avoid.
Big brands that have relied on TikTok videos to reach younger consumers do not appear to be panicking as they wait to see what happens. But they have started planning.
It's been 15 years since the last fatal crash of a U.S. airliner, but you wouldn't know that from a torrent of flight problems that made news in the last three months.
Abortion opponents want the high court to ratify a ruling from a conservative federal appeals court that would limit access to a medication called mifepristone, which was used in nearly two-thirds of abortions last year.
Annie Chechitelli, chief product officer at Turnitin, breaks down how students and teachers alike can learn from artificial intelligence – while still maintaining academic integrity.
Neiman Marcus Group CEO Geoffroy van Raemdonck talks luxury shopping and TikTok, why the company prefers to be private for now, and the benefits of flexible work arrangements.
Rebecca Walser, founder and CEO of Walser Wealth Management, discusses how geopolitical conditions, the bifurcated economy, and other volatility could weigh on markets.
